{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:22:30Z","timestamp":1778685750557,"version":"3.51.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004522"],"award-info":[{"award-number":["BX004522"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Respiratory failure due to SARS-CoV-2 has caused widespread mortality, creating an urgent need for effective treatments and a long-term need for antivirals for future emergent coronaviruses. Pharmacotherapy for respiratory viruses has largely been unsuccessful with the exception of early treatment of influenza viruses, which shortens symptom duration and prevents infection in close contacts. Under the rapidly evolving circumstances of the COVID-19 pandemic, most clinical trials of experimental treatments in the United States have focused on later stages of the disease process. Worldwide, the clinical studies of the most impactful drugs, remdesivir and dexamethasone in ACTT-1, RECOVERY, and Solidarity, have studied hospitalized patients. Less than half of clinical trials in the U.S. have investigated oral agents, and the majority have taken place in hospitals at a disease stage where the viral load is already decreasing. The limited success of treatments for respiratory viruses and the viral dynamics of COVID-19 suggest that an antiviral therapy with the greatest impact against pandemic coronaviruses would be orally administered, well-tolerated, target a highly conserved viral protein or host-coronavirus interaction and could be used effectively throughout the world, including resource-poor settings. We examine the treatment of respiratory viral infections and current clinical trials for COVID-19 to provide a framework for effective antiviral therapy and prevention of future emergent coronaviruses and call attention to the need for continued preclinical drug discovery.<\/jats:p>","DOI":"10.3389\/fmed.2020.596587","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:01:14Z","timestamp":1608624074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective"],"prefix":"10.3389","volume":"7","author":[{"given":"Angela Holly","family":"Villamagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Stone","family":"Doggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c","article-title":"Estimation of MERS-coronavirus reproductive number and case fatality rate for the Spring 2014 Saudi Arabia outbreak: insights from publicly available data","author":"Majumder","year":"2014","journal-title":"PLoS Curr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat Med."},{"key":"B5","first-page":"666","article-title":"Effects of ribavirin on measles","volume":"109","author":"Pal","year":"2011","journal-title":"J Indian Med Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbmt.2006.08.040","article-title":"Treatment of adenovirus disease in stem cell transplant recipients with cidofovir","volume":"13","author":"Neofytos","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.bmt.1703798","article-title":"Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the infectious diseases working party of the European group for blood and marrow transplantation","volume":"31","author":"Ljungman","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000181.pub2","article-title":"Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children","author":"Ventre","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2010-08-263400","article-title":"Management of RSV infections in adult recipients of hematopoietic stem cell transplantation","volume":"117","author":"Shah","year":"2011","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMc2022236","article-title":"Remdesivir for the treatment of covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med."},{"key":"B15","article-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","author":"Bennett","year":"2019"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/cid\/ciy860","article-title":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes","volume":"69","author":"Katzen","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1378\/chest.10-2792","article-title":"Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection","volume":"140","author":"Viasus","year":"2011","journal-title":"Chest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1086\/381128","article-title":"Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis","volume":"189","author":"Hayden","year":"2004","journal-title":"J Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review","volume":"3","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 \u2013interim WHO solidarity trial results","author":"Pan","year":"2020","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"B33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Monk","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","author":"Chen","year":"2020","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19 - preliminary report","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A real-time dashboard of clinical trials for COVID-19","volume":"2","author":"Thorlund","year":"2020","journal-title":"Lancet Digit Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11739-020-02345-9","article-title":"Camostat mesilate therapy for COVID-19","volume":"29","author":"Uno","year":"2020","journal-title":"Intern Emerg Med."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.997254","article-title":"Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics","author":"Gassen","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.22541\/au.158938595.50403411","article-title":"Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis","author":"Rajoli","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1101\/2020.03.20.999730","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.11.242834","article-title":"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic","author":"Good","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"B48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.15.203489","article-title":"Prophylactic and therapeutic inhibition of in vitro SARS-CoV-2 replication by oleandrin","author":"Plante","year":"2020","journal-title":"bioRxiv [Preprint]."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.17.20037432","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"B51","doi-asserted-by":"publisher","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial","volume":"25","author":"Lou","year":"2020","journal-title":"Eur J Pharm Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.forsciint.2008.05.002","article-title":"A fatal case of oleandrin poisoning","volume":"179","author":"Wasfi","year":"2008","journal-title":"Forensic Sci Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00414-005-0548-6","article-title":"A non-fatal oleander poisoning","volume":"119","author":"Pietsch","year":"2005","journal-title":"Int J Legal Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.15585\/mmwr.mm6944e1","article-title":"Transmission of SARS-COV-2 infections in households - tennessee and wisconsin, April-September 2020","volume":"69","author":"Grijalva","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2471\/BLT.11.101733","article-title":"Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico","volume":"90","author":"Gutierrez-Mendoza","year":"2012","journal-title":"Bull World Health Organ."},{"key":"B56","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3201\/eid2206.151037","article-title":"Debate regarding oseltamivir use for seasonal and pandemic influenza","volume":"22","author":"Hurt","year":"2016","journal-title":"Emerg Infect Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.028","article-title":"Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection","author":"Wei","year":"2020","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.596587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:01:17Z","timestamp":1608624077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.596587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":60,"alternative-id":["10.3389\/fmed.2020.596587"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.596587","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"article-number":"596587"}}